---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-083433"
form_type: "8-K"
ticker: null
cik: "0001600132"
company_name: "Bellerophon Therapeutics, Inc."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:14:02.184944+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bellerophon receives Nasdaq delisting notice over public shell status and bid price non-compliance

## Summary
- Nasdaq notified Bellerophon on July 19, 2023 of delisting effective July 28 unless hearing requested.
- Staff believes company is a 'public shell' and fails $1.00 bid price requirement (Rule 5550(a)(2)).
- Company plans to timely request a hearing; stock remains listed pending hearing outcome.
- Workforce reduction and exploration of strategic alternatives previously disclosed.

## SEC filing metadata
- accession: 0001104659-23-083433
- form_type: 8-K
- cik: 0001600132
- company_name: Bellerophon Therapeutics, Inc.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600132/000110465923083433/0001104659-23-083433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600132/000110465923083433/tm2321917d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-083433
- JSON: https://secwatch.observer/filing/0001104659-23-083433.json
- Plain text: https://secwatch.observer/filing/0001104659-23-083433.txt

## Key facts
- Listing & Compliance Notices
  Bellerophon Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5101
  source text: July 19, 2023, Bellerophon Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that in light of the Company’s previously disclosed workforce reduction plan and focus on exploring strategic alternatives, based upon the Staff’s belief that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101 and the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), the Company would be delisted from The Nasdaq Capital Market at the op
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465923083433/0001104659-23-083433-index.htm
- Listing & Compliance Notices
  Bellerophon Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: July 19, 2023, Bellerophon Therapeutics, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that in light of the Company’s previously disclosed workforce reduction plan and focus on exploring strategic alternatives, based upon the Staff’s belief that the Company is a “public shell” as that term is defined in Nasdaq Listing Rule 5101 and the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), the Company would be delisted from The Nasdaq Capital Market at the op
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600132/000110465923083433/0001104659-23-083433-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.